GlassScriptPhysician profile
Sandeep R Pandit
NPI 1194743716
$1,590.38
in general payments reported to CMS, 2019-2025
18 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $683 · 2024: $301 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904 · Consulting Fee: $525 · Education: $41.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.51 |
| Consulting Fee | $525.00 |
| Education | $41.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $525.00 | 2023 | Calquence |
| Merck Sharp & Dohme LLC | $118.86 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $112.95 | 2022-2024 | Lumakras |
| Pfizer INC. | $106.67 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $93.92 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $92.41 | 2024-2025 | |
| Eisai INC. | $69.07 | 2023-2025 | |
| Pharmaessentia USA Corporation | $69.00 | 2024-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $53.25 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $48.78 | 2023-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $46.29 | 2022-2025 | Trodelvy |
| Array Biopharma INC | $42.37 | 2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $40.45 | 2023-2024 | Erleada |
| Tempus Ai, INC | $24.11 | 2025 | Xt Cdx |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $18.19 | 2023 | Foundationone Cdx |
| Exelixis INC. | $17.98 | 2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2024 | Tazverik, Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Pandit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.